Multistep aggregation pathway of human interleukin-1 receptor antagonist: kinetic, structural, and morphological characterization
- PMID: 19134476
- PMCID: PMC2710017
- DOI: 10.1016/j.bpj.2008.10.002
Multistep aggregation pathway of human interleukin-1 receptor antagonist: kinetic, structural, and morphological characterization
Abstract
The complex, multistep aggregation kinetic and structural behavior of human recombinant interleukin-1 receptor antagonist (IL-1ra) was revealed and characterized by spectral probes and techniques. At a certain range of protein concentration (12-27 mg/mL) and temperature (44-48 degrees C), two sequential aggregation kinetic transitions emerge, where the second transition is preceded by a lag phase and is associated with the main portion of the aggregated protein. Each kinetic transition is linked to a different type of aggregate population, referred to as type I and type II. The aggregate populations, isolated at a series of time points and analyzed by Fourier-transform infrared spectroscopy, show consecutive protein structural changes, from intramolecular (type I) to intermolecular (type II) beta-sheet formation. The early type I protein spectral change resembles that seen for IL-1ra in the crystalline state. Moreover, Fourier-transform infrared data demonstrate that type I protein assembly alone can undergo a structural rearrangement and, consequently, convert to the type II aggregate. The aggregated protein structural changes are accompanied by the aggregate morphological changes, leading to a well-defined population of interacting spheres, as detected by scanning electron microscopy. A nucleation-driven IL-1ra aggregation pathway is proposed, and assumes two major activation energy barriers, where the second barrier is associated with the type I --> type II aggregate structural rearrangement that, in turn, serves as a pseudonucleus triggering the second kinetic event.
Figures








Similar articles
-
Biophysical characterization of structural properties and folding of interleukin-1 receptor antagonist.J Mol Biol. 2007 May 11;368(4):1187-201. doi: 10.1016/j.jmb.2007.02.031. Epub 2007 Feb 22. J Mol Biol. 2007. PMID: 17391700
-
High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics.J Pharm Sci. 2008 Aug;97(8):3005-21. doi: 10.1002/jps.21205. J Pharm Sci. 2008. PMID: 17924426
-
Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.Protein Sci. 2018 Jul;27(7):1191-1204. doi: 10.1002/pro.3382. Epub 2018 Mar 3. Protein Sci. 2018. PMID: 29388282 Free PMC article.
-
Conformation and side chains environments of recombinant human interleukin-1 receptor antagonist (rh-IL-1ra) probed by raman, raman optical activity, and UV-resonance Raman spectroscopy.J Pharm Sci. 2008 Jun;97(6):2228-41. doi: 10.1002/jps.21191. J Pharm Sci. 2008. PMID: 17914732
-
Tau aggregation is driven by a transition from random coil to beta sheet structure.Biochim Biophys Acta. 2005 Jan 3;1739(2-3):158-66. doi: 10.1016/j.bbadis.2004.09.010. Epub 2004 Nov 12. Biochim Biophys Acta. 2005. PMID: 15615635 Review.
Cited by
-
Identification of fibrillogenic regions in human triosephosphate isomerase.PeerJ. 2016 Feb 4;4:e1676. doi: 10.7717/peerj.1676. eCollection 2016. PeerJ. 2016. PMID: 26870617 Free PMC article.
-
Experimental Model System to Study pH Shift-Induced Aggregation of Monoclonal Antibodies Under Controlled Conditions.Pharm Res. 2016 Jun;33(6):1359-69. doi: 10.1007/s11095-016-1878-4. Epub 2016 Feb 29. Pharm Res. 2016. PMID: 26928669
-
Immunogenicity of therapeutic proteins: influence of aggregation.J Immunotoxicol. 2014 Apr-Jun;11(2):99-109. doi: 10.3109/1547691X.2013.821564. Epub 2013 Aug 6. J Immunotoxicol. 2014. PMID: 23919460 Free PMC article. Review.
-
Classification and characterization of therapeutic antibody aggregates.J Biol Chem. 2011 Jul 15;286(28):25118-33. doi: 10.1074/jbc.M110.160457. Epub 2011 Mar 25. J Biol Chem. 2011. PMID: 21454532 Free PMC article.
References
-
- Cleland J.F., Powell M.F., Shire S.J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 1993;10:307–377. - PubMed
-
- Carpenter J.F., Kendrick B.S., Chang B.S., Manning M.C., Randolph T.W. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol. 1999;309:236–255. - PubMed
-
- Fink A.L. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold. Des. 1998;3:R9–R23. - PubMed
-
- Manning M.C., Patel K., Borchardt R.T. Stability of protein pharmaceuticals. Pharm. Res. 1989;6:903–918. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources